CVT Shareholders Sue To Stop $1.4B Biotech Merger
Shareholders of CV Therapeutics have filed a proposed class action in a California state court to stop the company from carrying out a proposed $1.4 billion merger with Gilead Sciences, which...To view the full article, register now.
Already a subscriber? Click here to view full article